PMID- 23289150
OWN - NLM
STAT- MEDLINE
DCOM- 20131021
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 47
IP  - 10
DP  - 2012 Oct
TI  - [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
PG  - 1363-9
AB  - The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, 
      gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer 
      after single and multiple oral administration. Twelve patients with advanced 
      gastric cancer were recruited to the study. The dose of S-1 for each patient was 
      determined according to his/her body surface area (BSA). The dose for single 
      administration was 60 mg every subject. The dose for multiple administration for 
      one subject was as follows: 100 mg x d(-1) or 120 mg x d(-1), 28-days consecutive 
      oral administration. The pharmacokinetic parameters of tegafur, 5-fluorouracil, 
      gimeracil, potassium oxonate and uracil after single oral administration were as 
      follows: (2,207 +/- 545), (220.0 +/- 68.2), (374.9 +/- 103.0), (110.5 +/- 100.8) 
      and (831.1 +/- 199.9) ng x mL(-1) for Cmax; (11.8 +/- 3.8), (4.4 +/- 3.3), (7.8 
      +/- 5.1), (3.1 +/- 0.9) and (8.8 +/- 4.1) h for t1/2, respectively. After six 
      days oral administration, the average steady state plasma concentrations (Cav) of 
      tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 
      1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 
      141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 
      +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), 
      respectively. The cumulative urine excretion percentage of tegafur, 
      5-fluorouracil, gimeracil and potassium oxonate in urine within 48 h were (4.2 
      +/- 2.8) %, (4.7 +/- 1.6) %, (18.5 +/- 6.0) % and (1.7 +/- 1.2) %, repectively, 
      after single oral administration of S-1. The results exhibited that tegafur had 
      some drug accumulation observed, and gimeracil, potassium oxonate, 5-fluorouracil 
      and uracil had no drug accumulation observed.
FAU - Liu, He-ying
AU  - Liu HY
AD  - Department of PharmaceuticalAnalysis, China Pharmaceutical University, Nanjing, 
      China
FAU - Ding, Li
AU  - Ding L
FAU - Yu, Yong
AU  - Yu Y
FAU - Chu, Yan
AU  - Chu Y
FAU - Zhu, He
AU  - Zhu H
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - 0 (Pyridines)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 4R7FFA00RX (potassium oxonate)
RN  - 56HH86ZVCT (Uracil)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - U3P01618RT (Fluorouracil)
RN  - UA8SE1325T (gimeracil)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*pharmacokinetics
MH  - Capsules
MH  - Drug Combinations
MH  - Female
MH  - Fluorouracil/blood/urine
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Oxonic Acid/blood/*pharmacokinetics/urine
MH  - Pyridines/blood/urine
MH  - Stomach Neoplasms/blood/*metabolism/pathology/urine
MH  - Tegafur/blood/*pharmacokinetics/urine
MH  - Uracil/blood/urine
EDAT- 2013/01/05 06:00
MHDA- 2013/10/22 06:00
CRDT- 2013/01/05 06:00
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/05 06:00 [pubmed]
PHST- 2013/10/22 06:00 [medline]
PST - ppublish
SO  - Yao Xue Xue Bao. 2012 Oct;47(10):1363-9.